CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Tuesday

CRISPR Therapeutics (NASDAQ:CRSP) is projected to announce its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 11, 2026 at 12:00 AM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $51.31 on Tuesday. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $78.48. The company has a market capitalization of $4.89 billion, a price-to-earnings ratio of -9.18 and a beta of 1.72. The business has a 50-day moving average of $55.08 and a 200-day moving average of $58.27.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the transaction, the chief executive officer directly owned 134,201 shares in the company, valued at approximately $8,082,926.23. This trade represents a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CRSP. Orbis Allan Gray Ltd lifted its stake in CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the last quarter. State Street Corp lifted its position in shares of CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after buying an additional 859,334 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of CRISPR Therapeutics by 19.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 311,863 shares of the company’s stock valued at $20,269,000 after buying an additional 49,774 shares during the period. Tower Research Capital LLC TRC grew its position in shares of CRISPR Therapeutics by 189.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 64,946 shares of the company’s stock valued at $4,209,000 after buying an additional 42,477 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in CRISPR Therapeutics during the third quarter worth about $2,724,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

CRSP has been the subject of several recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Friday. Bank of America dropped their price target on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Wedbush decreased their price objective on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, November 5th. Royal Bank Of Canada raised their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Finally, Wells Fargo & Company set a $75.00 target price on CRISPR Therapeutics in a research report on Monday, October 13th. Twelve investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $67.85.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.